OncoHost Launches NSCLC Test in the U.S.
OncoHost, a diagnostics company centered on predictive biomarker development patient care, launched its non-small lung cancer (NSCLC) test.
OncoHost, a diagnostics company centered on predictive biomarker development patient care, launched its non-small lung cancer (NSCLC) test.
Medial EarlySign signed a new partnership with Roche to create innovative, evidence-based solutions for early detection of lung cancer.
A study shows proof-of-concept of using a drop of blood to reveal lung cancer, which may help diagnose early-stage lung cancer in asymptomatic patients.
A recent report showed less than half of community oncologists used biomarker testing for lung cancer — compared to 73% of academic clinicians.
Read MoreResearchers have developed novel artificial intelligence blood testing technology that detected over 90% of lung cancers from 800 samples.
Read MoreDelfi Diagnostics’s lung cancer screening technology, which analyzes genome-wide cell-free DNA fragmentation profiles, detected 90% of cases.
Read MoreThe new findings show the Percepta Nasal Swab, a first-of-its-kind genomic test, accurately classifies lung cancer risk in current or former smokers with lung nodules so that those with benign nodules may safely avoid unnecessary additional procedures.
Read MoreThe study showed that the rapid liquid biopsy NGS test was able to accurately detect actionable genomic alterations in patients with NSCLC with a turnaround time of only 72 hours.
Read MoreThe transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing.
Read MoreStudy to focus on using saliva in the analysis of cell-free circulating tumor DNA to accurately and noninvasively detect non-small cell lung cancer.
Read MoreThe test validation trial resulted in CyPath Lung specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer.
Read MoreThe group claim will also enable the test to be used as a CDx for any future approved EGFR TKI therapies targeting the same mutations.
Read MoreFDA approved FoundationOne Liquid CDx for three new companion diagnostic indications: Piqray in advanced or metastatic breast cancer; Rubraca in advanced ovarian cancer; and Alecensa in a certain type of metastatic non-small cell lung cancer.
Read MoreIdylla reduced EGFR mutation testing turnaround time by more than a week versus reference methods for patients with NSCLC.
Read MoreThermo Fisher Scientific’s Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.
Read MoreThe companion diagnostic will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients with HER2 mutations.
Read MoreThis is the first approval to combine two technologies—NGS and liquid biopsy—in one diagnostic in order to guide treatment decisions.
Read MoreIsraeli laboratories are approved to use molecular profiling assays for NSCLC patients using Thermo Fisher Scientific’s Oncomine Comprehensive Assay Plus.
Read More